Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis

NACompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

October 21, 2023

Study Completion Date

October 21, 2023

Conditions
Non-Alcoholic Fatty Liver DiseaseGlucagon ResistanceType 1 DiabetesObesity
Interventions
DIAGNOSTIC_TEST

Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon

"The test consists of two experimental study days:~Day 1: intravenous bolus-injection of glucagon (0.2 mg at time 0 minutes) evaluating the effect of exogenous glucagon on amino acid disappearance. Blood samples will be obtained from time -10 to 120 minutes.~Day 2: 45-minute intravenous infusion of mixed amino acids (331 mg/min/kg body weight from time 0-45 minutes) to evaluate the effect of endogenous glucagon on amino acid metabolism. Blood samples will be obtained from time -10 to 180 minutes.~All participants will be subjected to a magnetic resonance imaging scan to assess whole-liver steatosis, and a bioelectrical impedance analysis to assess body composition.~Following study inclusion and the magnetic resonance imaging scan, participants will be stratified into groups based on hepatic steatosis. Individuals with \<5.6 % hepatic steatosis will be classified as controls and individuals with ≥5.6 % hepatic steatosis will be classified as MASLD."

Trial Locations (1)

Unknown

Bispebjerg University Hospital, Copenhagen

All Listed Sponsors
collaborator

Bispebjerg Hospital

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

lead

University of Copenhagen

OTHER